PAC 1

Drug Profile

PAC 1

Alternative Names: Procaspase activating compound 1; VO-100

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vanquish Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Apoptosis stimulants; Caspase 3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Anaplastic astrocytoma; Glioblastoma; Haematological malignancies; Solid tumours

Most Recent Events

  • 01 Oct 2017 Phase-I clinical trials in Anaplastic astrocytoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03332355)
  • 01 Oct 2017 Phase-I clinical trials in Glioblastoma (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03332355)
  • 01 Oct 2017 Vanquish Oncology initiates enrolment in a phase I trial for Solid tumours and Haematological malignancies (Monotherapy, Second-line therapy or greater, Late-stage disease) in USA (NCT03332355)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top